Sept. 18, 2012 | Vol. 11 No. 183 | Full Issue in PDF Format
View the entire issue.
A district court judge has largely sided with Jazz Pharmaceuticals’ definitions for patents on its narcolepsy drug Xyrem, and the outcome looks like a “clear win” in Jazz’s legal struggle to prevent generic competition from Roxane Laboratories, one analyst says.
Regeneron Pharmaceutical’s Eylea is expected to win FDA approval later this week or early next week as a treatment for central retinal vein occlusion (CRVO), according to an analyst note from RBC Capital.
Impax Laboratories can market generic versions of Alza Corporation’s attention deficit hyperactivity disorder (ADHD) drug Concerta in 2013 under a settlement with the Johnson & Johnson (J&J) subsidiary.
Wockhardt is planning an immediate launch of its generic 15-mg and 30-mg delayed-release lansoprazole capsules, used to treat peptic ulcers.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.